Opinion|Videos|August 30, 2024
Insights on Conjugate Pneumococcal Vaccines
The vaccination experts analyze the impact of currently approved pneumococcal vaccines on otitis media prevention and compare the newer conjugate vaccines (PCV15 and PCV20) to their predecessors in terms of strain coverage and clinical efficacy.
Advertisement
Episodes in this series
- What effect do currently approved pneumococcal vaccines have on preventing otitis media?
- How do the newer conjugate vaccines (PCV15 and PCV20) compare to their predecessors in terms of strain coverage and clinical efficacy?
- What are your considerations for selecting between conjugate vaccines for adult patients who are vaccine-naïve?
- When would you use PCV20 instead of PCV15 and vice versa?
Advertisement
Related to this article
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
Advertisement
Advertisement
Trending on Pharmacy Times
1
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
2
Walgreens Adds Pharmacist Outreach, Coverage Help for GLP-1s
3
GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD
4
The Growing Role the Specialty Pharmacy Team Plays in Helping Breast Cancer Patients Navigate Treatment
5